Qilu Pharmaceutical Co., Ltd.: Neoplasms trials

The registry lists 25 Neoplasms studies with Qilu Pharmaceutical Co., Ltd. as lead sponsor. 14 are open to participants now and 0 have results posted.

Phase 1 22Phase 2 5Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationNot yet recruitingNCT06949761Phase 1/2
• Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid TumorsNot yet recruitingNCT06932094Phase 1
• A Study of QLM2011 in Subjects With Advanced Solid TumorsNot yet recruitingNCT06925659Phase 1
• A Study of QLS1209 in theTreatment of Patients With Advanced Solid TumorsNot yet recruitingNCT06872580Phase 1
• Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsNot yet recruitingNCT06446388Phase 2
• A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant TumorsNot yet recruitingNCT06394713Phase 1/2
• A Study of QL1706H in Patients With Advanced Solid TumorsNot yet recruitingNCT06047431Phase 1
• A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid TumorsNot yet recruitingNCT06041035Phase 1/2
• A Study of QLF3108 in Participants With Advanced Solid TumorRecruitingNCT06019013Phase 1
• Phase I Study of QLS1103 in Subjects With Advanced Solid TumorsRecruitingNCT05884801Phase 1
• A Phase I Study of QLP2117 in Subjects With Advanced Solid TumorsRecruitingNCT05830045Phase 1
• A Phase I Study of QLS12004 in Patients With Advanced Solid TumorsNot yet recruitingNCT05829616Phase 1
• Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.RecruitingNCT05488821Phase 1
• Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid TumorsRecruitingNCT05461287Phase 1
• Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 3
• A Phase I Study of QL1604 for Advanced Solid TumorsStatus unknownNCT05801094Phase 1
• A Phase I Study of QL1604 in Subjects With Advanced Solid TumorsStatus unknownNCT05649761Phase 1
• A Study of QLS31905 in Patients With Advanced Solid TumorsStatus unknownNCT05278832Phase 1
• A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid TumorsStatus unknownNCT05171790Phase 1
• QLF32004 Injection for the Treatment of Patients With Advanced Malignant TumorsStatus unknownNCT05108779Phase 1
• PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell MalignanciesStatus unknownNCT05003141Phase 1
• A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic MalignanciesStatus unknownNCT04954456Phase 1
• QL1604 Monotherapy for dMMR or MSI-H Advanced Solid TumorsStatus unknownNCT04326829Phase 2
• A Study of QL1706 in Subjects With Advanced Malignant TumorStatus unknownNCT04296994Phase 1
• A Study of PSB205 in Subjects With Advanced Solid TumorsStatus unknownNCT03986606Phase 1